Aevi Genomic Medicine announces completion of enrollment in part A of phase 2 ASCEND trial
Aevi Genomic Medicine announced it has completed enrollment in Part A of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset of pediatric and adolescent patients with ADHD, to confirm response to AEVI-001 in these patients. August 14, 2018